These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 27774824)

  • 1. Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.
    Kettle JG; Åstrand A; Catley M; Grimster NP; Nilsson M; Su Q; Woessner R
    Expert Opin Ther Pat; 2017 Feb; 27(2):127-143. PubMed ID: 27774824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.
    Kettle JG; Åstrand A; Catley M; Grimster NP; Nilsson M; Su Q; Woessner R
    Expert Opin Ther Pat; 2017 Feb; 27(2):145-161. PubMed ID: 27774822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
    Dymock BW; See CS
    Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
    Roskoski R
    Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective JAK1 inhibitor and selective Tyk2 inhibitor patents.
    Norman P
    Expert Opin Ther Pat; 2012 Oct; 22(10):1233-49. PubMed ID: 22971156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018).
    He X; Chen X; Zhang H; Xie T; Ye XY
    Expert Opin Ther Pat; 2019 Feb; 29(2):137-149. PubMed ID: 30621465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective JAK inhibitors in development for rheumatoid arthritis.
    Norman P
    Expert Opin Investig Drugs; 2014 Aug; 23(8):1067-77. PubMed ID: 24818516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
    Treliński J; Robak T
    Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders.
    Roskoski R
    Pharmacol Res; 2022 Sep; 183():106362. PubMed ID: 35878738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigational Janus kinase inhibitors.
    Tam CS; Verstovsek S
    Expert Opin Investig Drugs; 2013 Jun; 22(6):687-99. PubMed ID: 23432430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the discovery of selective JAK inhibitors.
    Menet CJ; Rompaey LV; Geney R
    Prog Med Chem; 2013; 52():153-223. PubMed ID: 23384668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tofacitinib ameliorates inflammation in a rat model of airway neutrophilia induced by inhaled LPS.
    Calama E; Ramis I; Domènech A; Carreño C; De Alba J; Prats N; Miralpeix M
    Pulm Pharmacol Ther; 2017 Apr; 43():60-67. PubMed ID: 28087469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK3 inhibitors for the treatment of inflammatory and autoimmune diseases: a patent review (2016-present).
    Chen C; Lu D; Sun T; Zhang T
    Expert Opin Ther Pat; 2022 Mar; 32(3):225-242. PubMed ID: 34949146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Janus kinase inhibitors for the treatment of myeloproliferative neoplasms.
    Rosenthal A; Mesa RA
    Expert Opin Pharmacother; 2014 Jun; 15(9):1265-76. PubMed ID: 24766055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors.
    Meyer SC; Levine RL
    Clin Cancer Res; 2014 Apr; 20(8):2051-9. PubMed ID: 24583800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toward selective TYK2 inhibitors as therapeutic agents for the treatment of inflammatory diseases.
    Menet CJ
    Pharm Pat Anal; 2014 Jul; 3(4):449-66. PubMed ID: 25291316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective JAK inhibitors.
    Dymock BW; Yang EG; Chu-Farseeva Y; Yao L
    Future Med Chem; 2014; 6(12):1439-71. PubMed ID: 25329199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.
    Vainchenker W; Leroy E; Gilles L; Marty C; Plo I; Constantinescu SN
    F1000Res; 2018; 7():82. PubMed ID: 29399328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains.
    Williams NK; Bamert RS; Patel O; Wang C; Walden PM; Wilks AF; Fantino E; Rossjohn J; Lucet IS
    J Mol Biol; 2009 Mar; 387(1):219-32. PubMed ID: 19361440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK inhibitors for rheumatoid arthritis.
    Kubo S; Nakayamada S; Tanaka Y
    Expert Opin Investig Drugs; 2023 Apr; 32(4):333-344. PubMed ID: 37014106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.